Collector
Giriş Yap
GSK is acquiring lung cancer biotech Nuvalent in its biggest deal in over a decade | Collector
GSK is acquiring lung cancer biotech Nuvalent in its biggest deal in over a decade

GSK is acquiring lung cancer biotech Nuvalent in its biggest deal in over a decade

The all-cash deal, GSK's largest in more than a decade, gives the British drugmaker two late-stage lung cancer drugs under FDA review

Go to News Site